Sysmex launches first IVD JAK2V617F Gene Mutation Testing for Myeloproliferative Neoplasms covered under health insurance in Japan: ipsogen JAK2 DX Reagent.https://www.sysmex.co.jp/en/news/2020/200106.html …
-
-
(QIAGEN is the exclusive worldwide licensee of intellectual property rights that cover the detection of the V617F JAK2 mutation for diagnostic purposes.)
Prikaži ovu nit -
Important milestone for many patients to be tested for the JAK2 V617F mutation which presence is established as one of the major diagnostic criteria for MPN in the WHO 2016 guideline for the classification of myeloid neoplasms and acute leukemia: https://doi.org/10.1182/blood-2016-03-643544 …
Prikaži ovu nit
Kraj razgovora
Novi razgovor -
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.